IMJUDO Injection 300mg (イジュド点滴静注300mg)

Nazione: Giappone

Lingua: inglese

Fonte: すりの適正使用協議会 RAD-AR Council, Japan

Compra

Scarica Foglio illustrativo (PIL)
01-03-2023

Principio attivo:

Tremelimumab (Genetical Recombination)

Commercializzato da:

AstraZeneca K.K

INN (Nome Internazionale):

Tremelimumab (Genetical Recombination)

Forma farmaceutica:

injection

Foglio illustrativo

                                Drug Information Sheet("Kusuri-no-Shiori")
Injection
Published: 03/2023
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
IMJUDO INJECTION 300MG
ACTIVE INGREDIENT:
Tremelimumab (Genetical Recombination)
DOSAGE FORM:
injection
IMPRINT OR PRINT ON WRAPPING:
EFFECTS OF THIS MEDICINE
This medicine binds to the T cell (immune cell) receptor (CTLA-4) ,
thereby is considered to
suppress tumor growth by enhancing tumor antigen-specific T cell
proliferation and activation.
It is usually used for for treatment of unresectable hepatocellular
carcinoma.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
If you have or have a history of autoimmune disease or interstitial
lung disease (including
radiation pneumonitis).
・If you are pregnant or breastfeeding.
・If you are taking any other medicinal products. (Some medicines may
interact to enhance or
diminish medicinal effects. Beware of over-the-counter medicines and
dietary supplements
as well as other prescription medicines.)
DOSING SCHEDULE (HOW TO TAKE THIS MEDICINE)
・
Your dosing schedule prescribed by your doctor is((         
           
to be written by a healthcare
professional
))
・In general, for adults, administer by intravenous infusion over 60
minutes only once in
combination with durvalumab (genetical recombination).
・Consult with the doctor for the treatment duration.
PRECAUTIONS WHILE TAKING THIS MEDICINE
POSSIBLE ADVERSE REACTIONS TO THIS MEDICINE
The most commonly reported adverse reactions include rash, itc
                                
                                Leggi il documento completo
                                
                            

Cerca alert relativi a questo prodotto